RYTM Rhythm Pharmaceuticals, Inc. Stock Quote

RYTM [NASD]

Index	-	P/E	-	EPS (ttm)	-1.29	Insider Own	2.98%	Shs Outstand	50.25M	Perf Week	-13.54%
Market Cap	481.25M	Forward P/E	-	EPS next Y	-3.38	Insider Trans	0.00%	Shs Float	49.53M	Perf Month	-28.76%
Income	-61.60M	PEG	-	EPS next Q	-0.83	Inst Own	98.70%	Short Float	7.58%	Perf Quarter	-36.15%
Sales	1.30M	P/S	370.20	EPS this Y	21.40%	Inst Trans	0.84%	Short Ratio	12.88	Perf Half Y	-54.10%
Book/sh	6.41	P/B	1.34	EPS next Y	-109.80%	ROA	-18.20%	Target Price	30.17	Perf Year	-73.57%
Cash/sh	5.88	P/C	1.47	EPS next 5Y	16.10%	ROE	-20.20%	52W Range	8.50 - 43.26	Perf YTD	-71.01%
Dividend	-	P/FCF	-	EPS past 5Y	-45.40%	ROI	-	52W High	-80.07%	Beta	1.24
Dividend %	-	Quick Ratio	14.30	Sales past 5Y	-	Gross Margin	72.80%	52W Low	1.41%	ATR	0.73
Employees	90	Current Ratio	14.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	24.86	Volatility	7.92% 6.65%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	8.80%	Profit Margin	-	Rel Volume	0.95	Prev Close	8.95
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 02 BMO	Payout	-	Avg Volume	291.51K	Price	8.62
Recom	2.60	SMA20	-27.43%	SMA50	-27.80%	SMA200	-51.53%	Volume	276,693	Change	-3.69%

Nov-19-21

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$50 → $15

Sep-14-21

Resumed

Goldman

Neutral

$14

Aug-04-21

Downgrade

Ladenburg Thalmann

Buy → Neutral

Aug-04-21

Downgrade

BofA Securities

Neutral → Underperform

$33 → $17

Nov-30-20

Downgrade

BofA Securities

Buy → Neutral

$27 → $33

Jan-08-20

Initiated

Goldman

Sell

$18

Jul-12-19

Upgrade

Stifel

Hold → Buy

$34

Jul-08-19

Initiated

Canaccord Genuity

Buy

$35

Mar-13-19

Initiated

Ladenburg Thalmann

Buy

$43

Sep-07-18

Resumed

Morgan Stanley

Overweight

Jun-25-18

Reiterated

Needham

Buy

$36 → $42

Jun-15-18

Reiterated

Needham

Buy

$32 → $36

Oct-30-17

Initiated

Needham

Buy

$32

Oct-30-17

Initiated

BofA/Merrill

Buy

$30

Nov-15-21 07:45AM	Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome GlobeNewswire
Nov-09-21 04:01PM	Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference GlobeNewswire
Nov-02-21 07:00AM	Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results GlobeNewswire +6.61%
Nov-01-21 04:01PM	Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021 GlobeNewswire +5.13%
Oct-20-21 08:00AM	Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021 GlobeNewswire
Oct-14-21 04:01PM	Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes GlobeNewswire
08:00AM	Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program GlobeNewswire
06:30AM	Scientist behind Vertex CF drugs launches new startup with Atlas Venture American City Business Journals
Oct-11-21 02:50PM	Here's Why We're Not Too Worried About Rhythm Pharmaceuticals' (NASDAQ:RYTM) Cash Burn Situation Simply Wall St.
Sep-22-21 10:30AM	Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting GlobeNewswire
Sep-21-21 07:57PM	CORRECTION: Rhythm Pharmaceuticals, Inc. GlobeNewswire
06:15PM	Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain GlobeNewswire
Sep-20-21 07:30AM	Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes GlobeNewswire
Sep-08-21 04:01PM	Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome GlobeNewswire
Sep-02-21 04:01PM	Rhythm Pharmaceuticals Announces CMO Transition GlobeNewswire
08:00AM	Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference GlobeNewswire
Aug-12-21 07:45AM	Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting GlobeNewswire
Aug-05-21 12:00PM	Rhythm Pharmaceuticals, Inc. (RYTM) Upgraded to Buy: Here's Why Zacks
08:00AM	Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Aug-03-21 07:01AM	Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results GlobeNewswire
06:59AM	Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity GlobeNewswire
Jul-29-21 08:00AM	Rhythm Pharmaceuticals Announces Senior Leadership Additions GlobeNewswire -6.29%
Jul-28-21 04:01PM	Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome GlobeNewswire
Jul-27-21 08:00AM	Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021 GlobeNewswire
Jul-26-21 05:20PM	Were Hedge Funds Right About Piling Into Rhythm Pharmaceuticals, Inc. (RYTM)? Insider Monkey
Jul-23-21 10:15AM	Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations Benzinga
08:50AM	Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency GlobeNewswire
Jul-22-21 08:00AM	Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE (setmelanotide) in Israel GlobeNewswire
Jul-12-21 09:41AM	Have Insiders Been Buying Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares? Simply Wall St.
May-27-21 08:00AM	Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-21-21 08:39AM	Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency GlobeNewswire
May-05-21 08:00AM	Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference GlobeNewswire
May-03-21 10:55AM	Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates Zacks
08:00AM	Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results GlobeNewswire
Apr-13-21 05:49AM	We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Needs To Drive Business Growth Carefully Simply Wall St.
Apr-09-21 02:16PM	7 Beaten Down Stocks with Significant Insider Buying InvestorPlace
Apr-07-21 08:00AM	Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference GlobeNewswire
Mar-20-21 11:30AM	Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021 GlobeNewswire
Mar-09-21 08:00AM	Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021 GlobeNewswire
Mar-01-21 08:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
Feb-24-21 08:30AM	Rhythm Pharmaceuticals to Present at Cowen & Co. 41st Annual Health Care Conference GlobeNewswire
Feb-12-21 04:12AM	What Kind Of Investors Own Most Of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)? Simply Wall St.
Feb-10-21 05:23PM	Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Feb-04-21 09:49PM	Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering GlobeNewswire
Feb-03-21 04:01PM	Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering GlobeNewswire
Jan-26-21 07:00AM	Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities GlobeNewswire -13.17%
Jan-19-21 08:00AM	Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts GlobeNewswire
Jan-05-21 08:17AM	Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M GlobeNewswire
08:00AM	Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director PR Newswire
Dec-22-20 07:00AM	Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes GlobeNewswire
Dec-11-20 08:15AM	Rhythm Pharmaceuticals Announces Appointments of Camille L. Bedrosian, M.D., and Lynn Tetrault, J.D., to its Board of Directors GlobeNewswire
Dec-10-20 11:44AM	Is RYTM A Good Stock To Buy Now? Insider Monkey
Dec-02-20 12:56PM	Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More Zacks
Nov-30-20 02:37PM	Rhythm (RYTM) Up on FDA Approval of Weight Management Drug Zacks +5.74%
Nov-29-20 04:59AM	Rhythm Pharmaceuticals IMCIVREE Gets FDA Stamp of Approval; Stifel Boosts Price Target TipRanks
Nov-27-20 01:19PM	How This Small Biotech Is Targeting Obesity And Why Shares Are Surging Investor's Business Daily +21.15%
07:30AM	Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency GlobeNewswire
Nov-04-20 04:30PM	Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 GlobeNewswire
Nov-02-20 08:00AM	Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results GlobeNewswire
Oct-30-20 07:30PM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology GlobeNewswire
Oct-28-20 08:00AM	Rhythm Pharmaceuticals Appoints Jennifer Chien as Executive Vice President, Head of North America GlobeNewswire
Oct-20-20 02:10PM	We Think Rhythm Pharmaceuticals (NASDAQ:RYTM) Can Afford To Drive Business Growth Simply Wall St.
Oct-09-20 08:40AM	Rhythm Pharmaceuticals (RYTM) Looks Good: Stock Adds 5.1% in Session Zacks
Oct-05-20 10:15AM	3 Strong Buy Healthcare Stocks With Major Catalysts Approaching TipRanks
Sep-14-20 04:01PM	Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International GlobeNewswire
Sep-09-20 08:00AM	Rhythm Pharmaceuticals to Present at Investor Conferences in September GlobeNewswire
Sep-01-20 08:38AM	Rhythm (RYTM) Soars: Stock Adds 9.4% in Session Zacks
Aug-06-20 08:00AM	Rhythm Pharmaceuticals to Present Virtually at Canaccord Genuity 40th Annual Growth Conference GlobeNewswire
Aug-03-20 08:00AM	Rhythm Pharmaceuticals Reports Second Quarter 2020 Financial Results GlobeNewswire +5.10%
Jul-27-20 08:00AM	Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations GlobeNewswire
Jul-20-20 07:30AM	Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer GlobeNewswire
Jul-16-20 08:00AM	Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolism GlobeNewswire
Jul-01-20 08:00AM	Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities GlobeNewswire
08:00AM	Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities GlobeNewswire
Jun-26-20 11:20AM	Hedge Funds Are Selling Rhythm Pharmaceuticals, Inc. (RYTM) Insider Monkey -8.07%
May-26-20 08:00AM	Rhythm Pharmaceuticals to Present Virtually at Upcoming Investor Conference in June GlobeNewswire
May-13-20 09:00AM	Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities GlobeNewswire
May-05-20 08:00AM	Rhythm Pharmaceuticals to Present Virtually at 2020 BofA Securities Health Care Conference GlobeNewswire
May-04-20 08:00AM	Rhythm Pharmaceuticals Reports First Quarter 2020 Financial Results GlobeNewswire +5.90%
Apr-21-20 12:14PM	We're Not Very Worried About Rhythm Pharmaceuticals's (NASDAQ:RYTM) Cash Burn Rate Simply Wall St.
Apr-07-20 08:00AM	Rhythm Pharmaceuticals to Present Virtually at Needham & Co. 19th Annual Healthcare Conference GlobeNewswire
Mar-30-20 08:00AM	Rhythm Pharmaceuticals Provides Updates on Leadership Transition and Business Operations GlobeNewswire
07:55AM	Rhythm Pharmaceuticals Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Setmelanotide in POMC and LEPR Deficiency Obesities GlobeNewswire
Mar-18-20 08:00AM	Rhythm Pharmaceuticals Receives Orphan Drug Designation from U.S. FDA for Setmelanotide for the Treatment of Alström Syndrome GlobeNewswire
Mar-02-20 08:00AM	Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire +7.02%
Feb-25-20 08:00AM	Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference GlobeNewswire +5.47%
Jan-07-20 01:11PM	Rhythm Pharmaceuticals stock falls on news CEO is leaving MarketWatch
07:57AM	The Daily Biotech Pulse: Xeris Jumps On Positive Data, Mixed Results For Merck's Keytruda-Chemo Combo In Lung Cancer, Intra-Cellular Announces Offering Benzinga
Jan-06-20 04:15PM	Rhythm Pharmaceuticals Announces Leadership Transition GlobeNewswire
Dec-17-19 05:05PM	Hedge Funds Are Dumping Rhythm Pharmaceuticals, Inc. (RYTM) Insider Monkey
Dec-05-19 08:00AM	Rhythm Pharmaceuticals Completes Enrollment of Pivotal Cohort in Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes GlobeNewswire +5.99%
Nov-22-19 07:09AM	Rhythm Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-13-19 08:01AM	Rhythm Pharmaceuticals to Present at Stifel 2019 Healthcare Conference GlobeNewswire
Nov-04-19 04:01PM	Rhythm Pharmaceuticals Announces Late-breaking Data from Phase 3 Trials of Setmelanotide in POMC and LEPR Deficiency Obesities at ObesityWeek 2019 GlobeNewswire
Nov-01-19 08:31AM	Rhythm Pharmaceuticals Reports Third Quarter 2019 Financial Results GlobeNewswire
Oct-30-19 08:20PM	Heres What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM) Insider Monkey
04:01PM	Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ObesityWeek® 2019 GlobeNewswire
Oct-23-19 12:27PM	Can We See Significant Institutional Ownership On The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Share Register? Simply Wall St.
Oct-18-19 12:32PM	Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-16-19 07:06AM	The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch Benzinga

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstrom syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Hunter C	Chief Financial Officer	Apr 21	Option Exercise	6.88	5,000	34,400	38,650	Apr 23 06:08 AM
Meeker David P	President and CEO	Mar 30	Buy	20.17	10,000	201,713	111,335	Mar 31 04:08 PM
Foley Todd	Director	Mar 15	Sale	25.10	1,000,000	25,100,000	909,258	Mar 16 05:13 PM
Smith Hunter C	Chief Financial Officer	Jan 19	Option Exercise	6.88	4,000	27,520	33,650	Jan 20 04:05 PM
RA CAPITAL MANAGEMENT, L.P.	Former 10% Owner	Dec 03	Sale	29.03	207,604	6,027,391	4,360,860	Dec 04 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience